Objective To observe the effect of preventing the recurrence of hepatitis B with the combination entecavir and hepatitis B immune globulin（HBIG）in the hepatitis B surface antigen（HBsAg）positive renal transplant receipts，which received the HBsAg positive allograft. Methods The clinical data of 30 cases renal transplant were retrospectively analyzed from January 2015 to August 2017. To prevent outbreak of hepatitis B in the early time，the stategry was that the recipients with HBsAg positive received the allograft with hepatitis B positive. Prior to the transplantation，the 100 ml HTK preservation solution with HBIG 400 U was perfused into the kidney through the renal artery. In addition，entecavir was used for prophylaxis postoperatively. All of them were followed up for 3 to 36 months，the graft function，liver function，HBV DNA，and recipient and graft survival rates were evaluated. Results Up to October 2017，with 6 ～ 36 months follow-up，the one year survival of allograft was 100%. The one year survival of recipients was 100%. Post-transplantation 3 weeks，the liver function was ALT（67±17）U/L，AST（53±12）U/L. Serum creatine was（112±67.3）μmol/L and HBV DNA was 1×102 ～ 5×108 copies/ml. HBV DNA increased significantly for two cases. One patients came to cirrhosis compensatory phase.There was no case with acute liver failure and liver tumor. Conclusion The HBIG plus entecavir in HBsAg positive recipients which received allograft from HBsAg positive donor can effectively prevent outbreak of hepatitis B in short term. The conclusion should be made by large clinical trials in the future.